1 Twenty-nine healthy volunteers participated in an experiment lasting for 8 weeks:
Introduction
Ciclazindol, 10-(m-chlorphenyl)-2,3,4,10-tetra-in animal tests used to detect potential antihydro-pyrimidol (1,2a)indol-10-ol (Swaisland depressant activity. Similarly to imipramine, et al., 1977; Kirby & Turner, 1977 ) is a tetra-ciclazindol antagonizes reserpine-and tetracyclic compound with activities very similar benazine-induced hypothermia in mice, potento those of established tricyclic antidepressants tiates metamphetamine-induced weight loss in 640 Felicity A. Kerr & E. Szabadi rats, and potentiates the noradrenaline-induced pressor response and the electrically induced contractions of the nictitating membrane in cats (Beckett et al., 1973) . Furthermore, ciclazindol is a potent blocker of the uptake of noradrenaline into brain slices, with little affinity for the 5-hydroxytryptamine uptake mechanism (Sugden, 1974) . In contrast to established tricyclic antidepressants (imipramine, desipramine, nortriptyline, amitriptyline), ciclazindol has no significant antimuscarinic, o-adrenoceptor blocking, anti-5-hydroxytryptamine, and anti-histamine properties (Waterfall et al., 1979) . A preliminary clinical trial supports predictions from preclinical studies that ciclazindol may be a clinically effective antidepressant with few autonomic side-effects (Ghose et al., 1978) . Furthermore, it has recently been reported that ciclazindol may have additional clinical usefulness as an anorectic and hypoglycaemic agent (Lean & Borthwick, 1983) .
Although observations in isolated tissue preparations can be used as predictors of the possible autonomic effects of drugs in humans, it is necessary to establish whether the predicted effects occur in humans treated with clinically relevant doses of the drugs in question. The human iris seems to be a particularly suitable pharmacological test system to study the effects of drugs acting on the autonomic nervous system. The iris is innervated by both adrenergic and cholinergic fibres, and the response of this tissue to topically applied agonists can easily be measured as a change in the diameter of the pupil. This method has already been used successfully to demonstrate the actions of conventional tricyclic antidepressants on the autonomic nervous system. Thus, it has been shown that desipramine and amitriptyline can antagonize the miosis evoked by pilocarpine (Szabadi et al., 1980) , and the mydriasis evoked by tyramine (Szabadi et al., 1975; Ghose, 1976; Shur & Checkley, 1982) , and phenylephrine (Shur & Checkley, 1982) , and that these drugs can potentiate the mydriasis evoked by noradrenaline (Szabadi et al., 1981) .
In the present study, we have examined the effects of chronic treatment with ciclazindol and desipramine on pupillary responses to methoxamine (a directly acting a-adrenoceptor stimulant), tyramine (an indirectly acting sympathomimetic amine), and pilocarpine (a directly acting muscarinic receptor stimulant) (see Szabadi et al., 1975 Szabadi et al., , 1980 Szabadi et al., , 1981 . The objective of the present study was to contribute to the pharmacological profile of ciclazindol in the autonomic nervous system of human subjects in order to be able to predict possible peripheral side effects and drug interactions. Furthermore, the investigation of the effects of chronic administration rather than of acute single doses (cf. e.g. Ehsanullah et al., 1977 ) is likely to mimic more faithfully the clinical situation where repeated single doses are administered over the period of several weeks (Ghose et al., 1978) .
A preliminary report of some of these results has been presented to the British Pharmacological Society (Kerr & Szabadi, 1979) .
Methods

Subjects
Twenty-nine healthy volunteers (22 males and seven females, aged 18 and 30 years) participated in the study. Eighteen subjects were blue-eyed, 10 subjects were hazel-eyed, and one subject was brown-eyed. None of the subjects had any previous history of eye-disease, and no other medication was being taken. All the subjects were informed about the nature and possible risks of the experiment, and all gave written consent. The study was approved by the Ethical Committee of Withington Hospital, Manchester.
Drugs
During Phase II of the experiment (see below), each subject took one of the following medications: ciclazindol hydrochloride (Wyeth Laboratories) 50 mg twice daily, desipramine hydrochloride (Geigy Pharmaceuticals) 50 mg twice daily, or lactose placebo twice daily. The three medications were dispensed in identical capsules for single-blind administration.
Measurement ofpupillary responses
Pupil diameter was measured using a photographic technique (Sneddon & Turner, 1969 increase in resting pupil diameter while placebo had no significant effect. Resting pupil diameter recovered to its original level after the administration of the antidepressants had been discontinued (Phase III).
Mydriasis evoked by methoxamine
The pre-treatment (Phase I) mydriatic response to methoxamine (mean ± s.e. mean, n = 16) was 1.49 ± 0.15 mm. The effects of the three treatment regimens on methoxamine-evoked mydriasis are shown in reached until about 10 days after the initiation of the treatment (Session 8). Similarly, the decline in the plasma level of desipramine following cessation of treatment was slow, and the presence of the drug could be detected even 2 weeks after discontinuation of medication (Session 16).
Discussion
Both ciclazindol and desipramine caused a small (approximately 10%) but significant increase in resting pupil diameter; pupil diameter recovered its original size after the discontinuation of antidepressant medication. The mydriatic effect of desipramine is well-documented in the literature (Szabadi et al., 1980; Shur & Checkley, 1982) , and has been attributed to the potentiation of the mydriatic effect of endogenous noradrenaline resulting from the blockade of uptake by the antidepressant (Szabadi et al., 1981) . Since ciclazindol, like desipramine, is a potent blocker of noradrenaline uptake (Sugden, 1974) , the same mechanism may underly the mydriatic effect of ciclazindol. Both ciclazindol and desipramine caused a considerable and significant reduction in the size of the mydriatic response to methoxamine. Since the antidepressants also caused an increase 644 Felicity A. 4 3. 
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Ciclazindol and desipramine on the pupil in resting pupil diameter (see above), an apparent reduction in the mydriatic response could have resulted from a decrease in the difference between resting pupil size and the size of the maximally dilated pupil. The operation of such a 'ceiling effect', however, could be excluded in the present experiment since the absolute size of the pupil (resting pupil diameter + mydriasis evoked by methoxamine) was less in the presence of the antidepressant than that observed during the pre-treatment phase of the experiment (see Figures 1 and 2) . The antagonism of the methoxamine-evoked mydriasis by desipramine is in agreement with earlier reports from this laboratory (Szabadi et al., 1981) , and is likely to reflect the blockade of postsynaptic al-adrenoceptors since methoxamine is a selective postsynaptic al-adrenoceptor stimulant (Langer, 1980) . Although ciclazindol has a lower potency than desipramine in blocking post-synaptic al-adrenoceptors (Sugden, 1974; Waterfall et al., 1979 ) the antagonism of the methoxamine-evoked mydriasis by ciclazindol in the present experiment indicates that oxladrenoceptor blockade can occur in humans treated with therapeutically recommended doses of the drug. A similar conclusion has been reached by Ghose et al. (1978) who found a significant correlation between the plasma concentration of ciclazindol and the reduction in the phenylephrine-evoked pressor response. Ciclazindol and desipramine antagonized the mydriatic response to tyramine. This observation is in agreement with previous reports of the antagonism of tyramine-evoked mydriasis by amitriptyline (Szabadi et al., 1975) and by desipramine (Shur & Checkley, 1982) . Since tyramine is an indirectly acting sympathomimetic amine (Trendelenburg, 1972) , the antagonism of the response is likely to reflect the uptake blocking property of the antidepressants; the reduction in the response to tyramine could have been further accentuated by the aoadrenoceptor blocking property of these drugs (see above).
Neither ciclazindol nor desipramine showed any antagonism of the miotic response to the muscarinic stimulant pilocarpine, thus confirming earlier observations with desipramine (Szabadi et al., 1980; Shur & Checkley, 1982) , and presumably reflecting the low affinity of both desipramine (Snyder & Yamamura, 1977) and ciclazindol (Waterfall et al., 1979) for the muscarinic receptor. An unexpected observation was, however, that the miotic response to pilocarpine was potentiated by both ciclazindol and desipramine. Shur & Checkley (1982) have also reported that the pilocarpine-evoked miosis was potentiated in depressed patients treated with desipramine. The authors attributed this observation to a 'baseline effect': as desipramine increased resting pupil diameter, there was 'greater room for constriction after pilocarpine'. Such an explanation would be appropriate if the pre-treatment (Phase I) responses to pilocarpine were of maximal or supra-maximal size. This, however, was not the case in our experiment: all the pre-treatment responses were submaximal (see Figure 3) . Furthermore, it is clear from all the measurements (see, for example, Figure 3 ) that the absolute size of the pupil (resting pupil diameter minus miotic response to pilocarpine) was smaller in the presence of the antidepressant than before treatment, suggesting a genuine potentiation of the response. (Any change in 645 the size of the response resulting from the baseline shift could approximate the pretreatment absolute pupil size, but never exceed it; for argument see Szabadi, 1977) . There is no immediate explanation for the potentiation. It is noteworthy, however, that no potentiation of the mydriatic response to pilocarpine was reported following single oral doses of desipramine (Szabadi et al., 1980) whereas potentiation was described in the studies involving chronic administration of the drug (present study, and Shur & Checkley, 1982) . It is possible, therefore, that the potentiation reflects some longterm adaptive changes in the iris to the presence of the antidepressant.
The twice-weekly assays of the plasma levels of the antidepressants showed that all the subjects complied with the medication throughout the study. There were some major differences between the plasma level profiles of ciclazindol and desipramine (see Table 2 ): (a) the steadystate plasma level of ciclazindol was attained much faster than that of desipramine; (b) the steady-state plasma level of ciclazindol was approximately ten times as high as that of desipramine; and (c) after discontinuation of treatment, the plasma level declined from steady-state much faster in the case of ciclazindol than in the case of desipramine. The steadystate plasma levels of the two antidepressants obtained in this study are similar to those reported in the literature (for ciclazindol, see Ghose et al., 1978 ; for desipramine, see Alexanderson, 1972; Rudorfer & Young, 1980) . The relatively 'slow' pharmacokinetic profile of desipramine (see also Alexanderson, 1972) could explain the slow recovery from some pharmacodynamic effects of desipramine after discontinuation of treatment: the partial preservation of the antagonism of the mydriatic response to methoxamine during the second week after cessation of treatment was paralleled by the presence of a lower than steady-state concentration of desipramine in the plasma (cf Tables 1 and 2 ).
